These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 23058032)
21. Physiopathology and management of osteonecrosis of the jaws related to bisphosphonate therapy for malignant bone lesions. A French expert panel analysis. Tubiana-Hulin M; Spielmann M; Roux C; Campone M; Zelek L; Gligorov J; Samson J; Lesclous P; Laredo JD; Namer M Crit Rev Oncol Hematol; 2009 Jul; 71(1):12-21. PubMed ID: 19070505 [TBL] [Abstract][Full Text] [Related]
23. [Bisphosphonates and osteonecrosis of the jaws]. Urade M Clin Calcium; 2007 Feb; 17(2):241-8. PubMed ID: 17272882 [TBL] [Abstract][Full Text] [Related]
24. Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Rizzoli R; Burlet N; Cahall D; Delmas PD; Eriksen EF; Felsenberg D; Grbic J; Jontell M; Landesberg R; Laslop A; Wollenhaupt M; Papapoulos S; Sezer O; Sprafka M; Reginster JY Bone; 2008 May; 42(5):841-7. PubMed ID: 18314405 [TBL] [Abstract][Full Text] [Related]
25. Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates. King AE; Umland EM Pharmacotherapy; 2008 May; 28(5):667-77. PubMed ID: 18447663 [TBL] [Abstract][Full Text] [Related]
26. Jaw osteonecrosis associated with aflibercept, irinotecan and fluorouracil: attention to oral district. Ponzetti A; Pinta F; Spadi R; Mecca C; Fanchini L; Zanini M; Ciuffreda L; Racca P Tumori; 2016 Nov; 102(Suppl. 2):. PubMed ID: 26350200 [TBL] [Abstract][Full Text] [Related]
27. Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Christodoulou C; Pervena A; Klouvas G; Galani E; Falagas ME; Tsakalos G; Visvikis A; Nikolakopoulou A; Acholos V; Karapanagiotidis G; Batziou E; Skarlos DV Oncology; 2009; 76(3):209-11. PubMed ID: 19212145 [TBL] [Abstract][Full Text] [Related]
28. The Role of Antiangiogenic Therapy in the Development of Osteonecrosis of the Jaw. Fantasia JE Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):547-53. PubMed ID: 26515736 [TBL] [Abstract][Full Text] [Related]
29. Osteonecrosis of the jaw complicating bisphosphonate treatment for bone disease in multiple myeloma: an overview with recommendations for prevention and treatment. Dickinson M; Prince HM; Kirsa S; Zannettino A; Gibbs SD; Mileshkin L; O'Grady J; Seymour JF; Szer J; Horvath N; Joshua DE Intern Med J; 2009 May; 39(5):304-16. PubMed ID: 19220531 [TBL] [Abstract][Full Text] [Related]
30. Osteonecrosis of the jaws secondary to bisphosphonate therapy: a case series. Kumar SK; Meru M; Sedghizadeh PP J Contemp Dent Pract; 2008 Jan; 9(1):63-9. PubMed ID: 18176650 [TBL] [Abstract][Full Text] [Related]
31. Osteonecrosis of the jaw related to bevacizumab. Estilo CL; Fornier M; Farooki A; Carlson D; Bohle G; Huryn JM J Clin Oncol; 2008 Aug; 26(24):4037-8. PubMed ID: 18711196 [No Abstract] [Full Text] [Related]
32. Osteonecrosis of the jaw. Watts NB; Marciani RD South Med J; 2008 Feb; 101(2):160-5. PubMed ID: 18364618 [TBL] [Abstract][Full Text] [Related]
33. The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors. Dodson TB Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):509-16. PubMed ID: 26362367 [TBL] [Abstract][Full Text] [Related]
34. Bisphosphonate-associated osteonecrosis of the jaw: conclusions based on an analysis of case series. Landesberg R; Wilson T; Grbic JT Dent Today; 2006 Aug; 25(8):52, 54-7. PubMed ID: 16925161 [TBL] [Abstract][Full Text] [Related]
35. Bisphosphonate-related osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients. Kyrgidis A; Vahtsevanos K; Koloutsos G; Andreadis C; Boukovinas I; Teleioudis Z; Patrikidou A; Triaridis S J Clin Oncol; 2008 Oct; 26(28):4634-8. PubMed ID: 18574158 [TBL] [Abstract][Full Text] [Related]
36. Patients with bisphosphonates-associated osteonecrosis of the jaw have reduced circulating endothelial cells. Allegra A; Oteri G; Nastro E; Alonci A; Bellomo G; Del Fabro V; Quartarone E; Alati C; De Ponte FS; Cicciù D; Musolino C Hematol Oncol; 2007 Dec; 25(4):164-9. PubMed ID: 17577204 [TBL] [Abstract][Full Text] [Related]
37. Incidence of bisphosphonate-associated osteonecrosis of the jaws in breast cancer patients. Walter C; Al-Nawas B; du Bois A; Buch L; Harter P; Grötz KA Cancer; 2009 Apr; 115(8):1631-7. PubMed ID: 19156913 [TBL] [Abstract][Full Text] [Related]
38. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Boonyapakorn T; Schirmer I; Reichart PA; Sturm I; Massenkeil G Oral Oncol; 2008 Sep; 44(9):857-69. PubMed ID: 18282788 [TBL] [Abstract][Full Text] [Related]
39. Recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonates. Bagán J; Blade J; Cozar JM; Constela M; García Sanz R; Gómez Veiga F; Lahuerta JJ; Lluch A; Massuti B; Morote J; San Miguel JF; Solsona E Med Oral Patol Oral Cir Bucal; 2007 Aug; 12(4):E336-40. PubMed ID: 17664922 [No Abstract] [Full Text] [Related]
40. [Bisphosphonate-induced osteonecrosis of the jaws--a guide to diagnosis, therapy and prevention of BON in dental practice]. Dannemann C; Grätz KW; Zwahlen RA Schweiz Monatsschr Zahnmed; 2008; 118(2):113-23. PubMed ID: 18361180 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]